On April 4, 2024 Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors to target escape mutations in hematologic and solid malignancies, reported the clearance from the Human Research Ethics Committee in Australia for lomonitinib (ZE46-0134) allowing the company to proceed with a Phase I clinical trial in relapsed/refractory (R/R) AML (Press release, Eilean Therapeutics, APR 4, 2024, View Source [SID1234650300]). Lomonitinib is a highly potent and selective plan-FLT3/IRAK4 inhibitor that targets clinically relevant FLT3 mutations and putative escape pathways.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This is a major milestone for the Eilean team, as we continue to progress an accelerated development of lomonitinib," stated Iain Dukes, Chief Executive Officer of Eilean Therapeutics. "Given the safety profile, extended half-life and target engagement demonstrated in a healthy volunteer study, we look forward to initiating our clinical trial and testing our approach in R/R AML patients."